Zymeworks (ZYME) Common Equity (2021 - 2026)

Zymeworks (ZYME) has 6 years of Common Equity data on file, last reported at $163.6 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 49.66% year-over-year to $163.6 million; the trailing twelve-month figure through Mar 2026 stood at $163.6 million (down 49.66% YoY), and the FY2025 full-year result was $268.5 million, down 20.74% from the prior year.
• Common Equity eased to $163.6 million in Q1 2026, from $268.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $493.0 million in Q4 2022 to a low of $163.6 million in Q1 2026.
• A 5-year average of $350.0 million and a median of $338.8 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 136.06% in 2023 and sank 49.66% in 2026, its largest moves.
• Tracing ZYME's Common Equity over 5 years: stood at $493.0 million in 2022, then retreated by 5.71% to $464.8 million in 2023, then decreased by 27.12% to $338.8 million in 2024, then retreated by 20.74% to $268.5 million in 2025, then slumped by 39.07% to $163.6 million in 2026.
• Business Quant data shows ZYME's Common Equity at $163.6 million in Q1 2026, $268.5 million in Q4 2025, and $320.1 million in Q3 2025.